Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)
Phase 1 Completed
15 enrolled 21 charts
Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors
Phase 1 Completed
18 enrolled
Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG
Phase 2 Completed
32 enrolled 16 charts
Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma
Phase 2 Completed
47 enrolled 14 charts
Retrospective Review of FDG PET MRI Management of Patients With Muscle Invasive Bladder Cancer
Completed
15 enrolled
Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer
Phase 2 Completed
60 enrolled 24 charts
Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
Phase 2 Completed
8 enrolled 16 charts
Interdisciplinary Case-Control Study of Bladder Cancer in Spain
Completed
2,925 enrolled
Follow-Up of Bladder Cancer Patients From the New England Study of Environment and Health
Completed
68 enrolled
Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers
Phase 2 Completed
43 enrolled 12 charts
Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer
Phase 2 Completed
31 enrolled 21 charts
TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma
Phase 2 Completed
13 enrolled 15 charts
Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy for Gynecological Cancer, Bladder Cancer, Colorectal Cancer, or Anal Cancer
Phase NA Completed
177 enrolled
Cognitive Testing of Tobacco Use Measurement Items for Administration With Cancer Patients and Survivors
Completed
30 enrolled 13 charts
LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium
Phase 2 Completed
22 enrolled 7 charts
Pazopanib in Treating Patients With Metastatic Urothelial Cancer
Phase 2 Completed
19 enrolled 8 charts
Radiation Therapy, Chemotherapy, or Observation in Treating Patients With Bladder Cancer
Phase 3 Completed
Eflornithine in Treating Patients With Bladder Cancer
Phase 3 Completed
450 enrolled
Radiation Therapy With or Without Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer
Phase 3 Completed
350 enrolled
Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer
Phase 2 Completed
45 enrolled
R115777 in Treating Patients With Advanced Bladder Cancer
Phase 2 Completed
Radiation Therapy With or Without Carbogen and Niacinamide in Treating Patients With Bladder Cancer
Phase 3 Completed
330 enrolled
Care of Cancer Patients With Bowel Injury Caused by Radiation Therapy to the Pelvis
Phase NA Completed
250 enrolled
Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment
Phase 2 Completed
41 enrolled
Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer
Phase 2 Completed
Suramin in Treating Patients With Recurrent Bladder Cancer
Phase 1 Completed
15 enrolled
Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma
Phase 2 Completed
40 enrolled
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
Phase 1 Completed
Paclitaxel in Treating Patients With Early-Stage Bladder Cancer
Phase 1/2 Completed
Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer
Phase 3 Completed
Loop Resectoscope in Treating Patients With Bladder Cancer or Benign Prostatic Hyperplasia Who Are Undergoing Transurethral Resection
Phase NA Completed
24 enrolled
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Phase 1 Completed
15 enrolled
Celecoxib in Treating Patients With Bladder Cancer
Phase 2/3 Completed
152 enrolled
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Phase 1 Completed
24 enrolled
Decitabine in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
24 enrolled
AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer
Phase 2 Completed
Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer
Phase 2 Completed
45 enrolled
Gene Therapy in Treating Patients With Advanced Bladder Cancer
Phase 1 Completed
24 enrolled
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Phase 1 Completed
75 enrolled
Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer
Phase 2 Completed
40 enrolled
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
75 enrolled
Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer
Phase 2 Completed
80 enrolled
A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder
Phase 1 Completed
18 enrolled
Bladder Cancer Case Control Study of Arsenic in Water
Completed
600 enrolled